Media headlines about Pain Therapeutics (NASDAQ:PTIE) have been trending somewhat positive this week, Accern Sentiment Analysis reports. Accern scores the sentiment of media coverage by analyzing more than twenty million blog and news sources in real time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Pain Therapeutics earned a media sentiment score of 0.21 on Accern’s scale. Accern also gave news articles about the biopharmaceutical company an impact score of 46.0945547765293 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the next few days.

Pain Therapeutics (NASDAQ:PTIE) traded up $0.04 during trading on Tuesday, hitting $4.10. The company had a trading volume of 70,900 shares, compared to its average volume of 174,516. Pain Therapeutics has a fifty-two week low of $3.10 and a fifty-two week high of $9.31.

Pain Therapeutics (NASDAQ:PTIE) last released its quarterly earnings results on Wednesday, November 1st. The biopharmaceutical company reported ($0.40) earnings per share (EPS) for the quarter. research analysts predict that Pain Therapeutics will post -2.2 EPS for the current fiscal year.

PTIE has been the subject of a number of analyst reports. Zacks Investment Research cut Pain Therapeutics from a “buy” rating to a “hold” rating in a report on Tuesday, September 19th. ValuEngine cut Pain Therapeutics from a “sell” rating to a “strong sell” rating in a report on Friday.

ILLEGAL ACTIVITY WARNING: “Somewhat Favorable Press Coverage Somewhat Unlikely to Affect Pain Therapeutics (PTIE) Stock Price” was originally published by TheOlympiaReport and is the sole property of of TheOlympiaReport. If you are accessing this story on another publication, it was illegally stolen and reposted in violation of U.S. & international copyright and trademark legislation. The original version of this story can be viewed at

About Pain Therapeutics

Pain Therapeutics, Inc is a biopharmaceutical company. The Company is focused on drug development efforts on disorders of the nervous system, such as chronic pain. The Company’s lead drug candidate, REMOXY, is an abuse-deterrent, oral formulation of oxycodone (CII). The Company’s other products is FENROCK.

Insider Buying and Selling by Quarter for Pain Therapeutics (NASDAQ:PTIE)

Receive News & Ratings for Pain Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pain Therapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.